Skip to content
2000
Volume 13, Issue 3
  • ISSN: 1871-5206
  • E-ISSN: 1875-5992

Abstract

Endocrine therapy has developed rapidly and become most effective and clearly target form of adjuvant therapy for hormone sensitive breast cancer. Adjuvant endocrine therapy for breast cancer can be given after surgery or radiotherapy, and also prior, or subsequent to chemotherapy. Current commonly used drugs for adjuvant endocrine therapy can be divided into following three classes: selective estrogen receptor modulators (SERMs), aromatase inhibitors (AIs) and selective estrogen receptor down-regulators (SERDs). Unfortunately, tumor cells may develop resistance to endocrine therapy, which become a major obstacle limiting the success of breast cancer treatment. The complicated crosstalk, both genomic and nongenomic, between estrogen receptor and growth factors was considered to be a crucial factor contributing to endocrine resistance. However, the progression of resistance to endocrine therapy supposes to be a progressive, step-wise procedure and the underlying mechanism remains unclear. In this review, we would summarize the possible biology and molecular mechanisms that underlie endocrine resistance, and also some novel strategies to overcoming this issue.

Loading

Article metrics loading...

/content/journals/acamc/10.2174/187152013804910398
2013-03-01
2025-05-02
Loading full text...

Full text loading...

/content/journals/acamc/10.2174/187152013804910398
Loading

  • Article Type:
    Research Article
Keyword(s): AIs; Endocrine resistance; Endocrine therapy; Estrogen receptor; HER2; SERDs; SERMs
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test